Professor Mitchell Lazar receives the 2019 Rolf Luft Award

February 13, 2019

Professor Mitchell Lazar at Perelman School of Medicine, University of Pennsylvania, Philadelphia has been selected as recipient of the Rolf Luft Award 2019. The Prize Lecture “Nuclear Receptors, Circadian Rhythms, and Metabolism" will be held by Professor Lazar at the Prize Ceremony, in Nobel Forum, on May 8th, 2019.

Rolf Luft Award is awarded annually by The Karolinska Institutet for outstanding scientific contribution in endocrinology and diabetes.

Learn more about the award

Illuminating Genetic Variants’ Causal Role in Response to Diabetes Drug

January 24, 2019

A team led by Mitchell Lazar, MD, PhD, director of the Institute for Diabetes, Obesity, and Metabolism, identified a single nucleotide polymorphism that affected whether the diabetes drug Avandia would cause a rise in cholesterol levels. “We went beyond just association, which is easy and most studies do [and] showed a causal relationship,” said Lazar. "We clearly showed that the single difference is responsible, statistically at least, for cholesterol increases.”

Read the BioWorld article

Using Genetics of Human Fat Cells to Predict Response to Anti-Diabetes Drugs

January 11, 2019

Mitch Lazar lab Genetic Variation

Drugs called thiazolidinediones (TZDs) reverse insulin resistance in patients with type 2 diabetes by targeting the activity of a receptor protein. However, an array of side effects, including weight gain, edema, and high cholesterol, limits their use in the clinic. In a new study published in Cell Stem Cell, a team of researchers led by Mitchell Lazar, MD, PhD,have demonstrated — using fat cells derived from human stem cells — that individual genetic variation can be used to predict whether the TZD rosiglitazone will produce the unwanted side effect of increasing cholesterol levels in certain individuals.

Read More: Penn Medicine News Release

Experimental Treatment for Type 1 Diabetes Avoids Pancreas Transplant

January 3, 2019

Michael Rickels, MD quoted in Inquirer

The Philadelphia Inquirer featured research for treating type 1 diabetes with pancreatic islet cell transplantation, which has resulted in some patients no longer needing insulin to manage their disease. Ali Naji, MD, PhD, director of the Pancreatic Islet Cell Transplantation Program, and Michael Rickels, MD, medical director of the program, are quoted.

Learn more - Philadelphia Inquirer

Diabetes Awareness Month: The Past, Present and Future of Diabetes Treatment

November 16, 2018

Diabetes Awareness

In the last 20-plus years, there has been a rapid acceleration of research and technology to make the lives of people with diabetes easier to manage. One promising treatment approach currently being developed is islet cell transplant. Michael Rickels, MD, medical director for the Pancreatic Islet Cell Transplantation Program at the Hospital of the University of Pennsylvania, notes, “this therapy has been life-changing and really transformative” for patients who are debilitated by glycemic lability and frequent, severe hypoglycemia.

Learn More | ABC News